Eli Lilly just sued six sellers of retatrutide. The catch is that the drug isn’t approved anywhere, so there is no legitimate version to buy. Whatever these sites are shipping came from outside the drug supply.
On August 12, Eli Lilly filed six lawsuits against U.S. sellers of retatrutide, its next weight-loss drug. Four are peptide vendors you may have scrolled past on a checkout page: Astra Peptides, Legendary Peptides, Texas Peptides, and Lone Star Peptide. The other two are a med-spa, Aesthetic Envy, and a compounding pharmacy, Striker Pharmacy. Several ship under the “research use only” label. Lilly also said it had referred more than 200 individuals and businesses to the FDA, the Justice Department, and state licensing boards, and flagged more than 14,000 websites and social posts across more than a hundred countries.
Update (August 12): The complaints are now public, and they run on two different theories. Lilly sues the compounding pharmacy under eight states’ consumer-protection laws for selling an unapproved “new drug,” and the med-spa under federal false-advertising law for marketing retatrutide as a “cutting-edge therapy” that “outperforms semaglutide and tirzepatide” while never disclosing it isn’t approved. Both lean on a reputational argument: that harm from black-market retatrutide, including Reddit posts Lilly quotes of heart rates dropping to 43 beats a minute and hospitalizations from contamination, will teach the public to fear the molecule itself and damage its eventual approved version. Five of the six filings are public:
| Defendant | Court / case no. | Filing |
| Striker Pharmacy (pharmacy) | S.D. Tex., 4:26-cv-06563 | Read |
| Aesthetic Envy (med spa) | E.D. Cal., 2:26-cv-01347 | Read |
| Legendary Peptides | E.D. Tex., 1:26-cv-00347 | Read |
| Lone Star Peptide | S.D. Tex., 4:26-cv-06562 | Read |
| Texas Peptides | W.D. Tex., 5:26-cv-05146 | Read |
| Astra Peptides | W.D. Tex. (not filed publicly) | pending |
The vendor filings are worth skimming just for how much the sellers handed Lilly. Legendary’s owner posted that he “increased dose and frequency too aggressively to push through the chaos of the holidays” and felt “Lethargy. Fatigue.” (¶46). Texas Peptides brands itself a “Texas-Built Research Reagent Supplier” while actually being a Wyoming corporation (¶11). And a lot of the evidence is the sellers’ own screenshots, reproduced right in the complaints:
And Lilly is not only suing. It is also leaning on the businesses these sellers depend on to operate: the social and e-commerce platforms, the credit-card companies and payment processors, the shipping and logistics carriers. It is asking all of them to cut the sellers off. That aims at a real weak point. Peptide sellers have always had trouble keeping a credit-card processor, which is why so many of them run on crypto or PayPal. Choke the payment rails and the business gets harder to run whether or not any single lawsuit lands.
Retatrutide is not approved, in the United States or anywhere else. It is still in Phase 3 trials. There is no legitimate version of it to counterfeit, which means the usual “real drug versus fake drug” framing does not apply. Whatever is being sold as retatrutide came from outside the regulated supply. Lilly’s own chief medical officer called it “entirely unverified, unapproved and not worth the risk.”
That includes Striker Pharmacy. A licensed pharmacy keeps inspection records, and that is real. But compounding an unapproved investigational molecule is not something the license covers, so a pharmacy’s name on the vial does not move retatrutide anywhere. Lilly’s allegation is that it sold a drug no one is allowed to sell yet.
This is not only Lilly. A week earlier, a Dutch court ordered a company to stop selling compounded semaglutide as a nasal spray, an unapproved form of the drug in Ozempic and Wegovy. Semaglutide is approved and retatrutide is not, so the two cases are not the same problem. But both makers are now in court trying to pull unauthorized copies off the market.
Get the next one in your inbox
I cover the latest GLP-1 trials and access changes weekly. Free, no spam, unsubscribe whenever.
I inject a compounded hormone myself twice a week, so I am not going to tell you compounded means dangerous. It doesn’t. What separates a real pharmacy from a gray-market seller is not how pure the drug is. It is whether anyone is required to inspect the place and write down what they find. A compounding pharmacy leaves a paper trail, sometimes an unflattering one. A “research use only” website leaves none: no one who has to test it for sterility, and no recall when a batch goes wrong.
And say the vial is clean. There is still the person holding the syringe. When a University of Connecticut team watched twenty people reconstitute and inject semaglutide themselves, on average they got fewer than half the steps right: expired or cloudy vials used anyway, mixed with the wrong amount of water, the needle put into muscle instead of the fat under the skin, no alcohol swab on the vial top or the skin. The younger, most confident volunteers kept their confidence even after they fumbled it.
So should you buy the retatrutide on that website? I wouldn’t. Not only because it’s illegal to sell, and not because you would be the one in trouble; the enforcement is aimed at the sellers, not at buyers like you. I wouldn’t because you cannot check the one thing that matters. Even the licensed pharmacy in Lilly’s complaint could only give you its name, and for a drug no one is allowed to sell yet, that name is worth nothing. You have no way to confirm who made it, what dose is in the vial, or whether it is sterile. Maybe it is exactly what the seller says. You are taking the seller’s word for all of it, on a drug its own maker will not sell you until the trials are done.